Healthcare Fraud In The Age Of Telemedicine: New Risks, Old Laws
A telehealth physician may evaluate a patient by video, review records uploaded from another state, prescribe medication electronically, and never see the claim submitted afterward. Federal investigators can still reconstruct the encounter from platform logs, prescribing records, marketing files, and claims data and argue that the technology helped conceal a fraudulent operation.
The electronic trail often extends far beyond what the physician personally handled. Virtual care changes how evidence is created, stored, and attributed across a healthcare platform. Guidance from an experienced Florida healthcare fraud lawyer can help establish what occurred during the clinical encounter, what happened elsewhere on the platform, and which decisions can actually be tied to the physician.
Older Fraud Statutes Still Reach Virtual Care
Federal healthcare fraud does not depend on whether the patient sat across from the physician in an examination room. 18 U.S.C. § 1347 applies to knowing and willful schemes involving the delivery of or payment for healthcare benefits, items, or services, including claims arising from telehealth encounters.
Virtual care creates a much different evidentiary trail from a traditional office visit. Login histories, encounter timestamps, electronic questionnaires, prescribing records, claims data, and communications between the physician and platform operator can allow investigators to reconstruct the sequence in remarkable detail.
That record may still leave important gaps. A login time does not show what outside records the physician reviewed beforehand, whether the patient had been treated previously, or what communications occurred before the video connection began. The final electronic record can therefore appear more complete than the information it actually captures.
Encounter Length Can Be Used to Question Medical Necessity
Telehealth platforms often record time with unusual precision. Investigators can identify when a physician logged in, how long the patient interaction lasted, and how quickly an order or prescription followed.
Patterns of brief encounters may be used to argue that meaningful medical judgment was impossible. Repeated visits of similar length can also be portrayed as a standardized process built to generate orders or claims rather than evaluate patients individually.
A timestamp captures only part of the encounter. Outside records, questionnaires, laboratory results, medication histories, and prior visits may already have been reviewed before the live interaction began. A short video call can sit within a much longer clinical review.
Follow-up activity may add another layer. Messages exchanged after the visit, medication adjustments, referrals, and later testing can show that the physician continued evaluating the patient after the platform recorded the formal encounter as complete.
Remote Prescribing Brings a Separate Federal Risk
Controlled-substance prescribing creates issues beyond ordinary healthcare billing. 21 U.S.C. § 829(e) addresses controlled substances prescribed through the Internet and generally requires a valid prescription issued for a legitimate medical purpose in the usual course of professional practice, while recognizing statutory telemedicine circumstances.
The federal framework has continued to change. DEA and HHS extended the current telemedicine flexibilities through December 31, 2026, allowing certain DEA-registered practitioners to prescribe Schedule II-V controlled substances through qualifying telemedicine encounters without first conducting an in-person medical evaluation, subject to applicable federal and state requirements.
Investigators reviewing remote prescriptions need to account for the rules in effect when the prescription was issued. A prescribing decision made under one regulatory framework may look very different if measured against requirements adopted later.
Patient-level records also matter. Dosage, refill frequency, diagnosis, prior treatment, follow-up, and changes in symptoms can explain why medication was started, continued, or adjusted rather than leaving prescribing volume to stand in for clinical intent.
Online Questionnaires Can Become Part of the Government’s Case
A telehealth patient may answer extensive questions before speaking with a physician. Those responses can supply symptoms, medical history, medication information, and other facts used during the encounter.
Investigators may examine whether the questionnaire gathered information or effectively predetermined the result. A workflow that directs most patients toward the same medication, laboratory test, or product can be portrayed as a sales process with physician approval added near the end.
Platform records can show whether the doctor could reject the recommendation, ask for additional information, change the proposed treatment, or require another encounter. Rejection rates and edits to prepopulated recommendations may also show how often physicians departed from the platform’s initial pathway.
Those details provide a more complete picture than the questionnaire alone. A heavily automated intake process does not establish that the final clinical decision was automatic.
Marketing Companies Can Influence How the Encounter Is Viewed
Telehealth businesses often rely on digital advertising, lead generators, call centers, and outside marketing companies to acquire patients. Those relationships can become part of the criminal theory when investigators believe patient acquisition was tied to reimbursable services.
Federal agents may compare marketing payments with physician orders and downstream claims. A per-lead arrangement can take on a different appearance if the marketer receives more when the patient produces a prescription, test, device, or other reimbursable service.
The physician may have had no involvement in those contracts. Platform permissions, emails, compensation records, and organizational documents can show whether the doctor knew how patients were acquired or how the marketing company was paid.
Call-center activity can create another evidentiary layer. Recorded calls or scripts may show that patients were steered toward a product before the physician became involved, placing the origin of the recommendation outside the clinical encounter.
Platform Workflows Can Hide Who Made the Decision
Telemedicine distributes responsibility across software as well as people. A platform may populate a proposed diagnosis, route an order, select a pharmacy, apply billing information, or generate documentation before the physician finishes the encounter.
The final electronic record can make those actions look like one continuous physician-controlled process. Automated fields and system-generated language may obscure which entries came from the doctor, which came from intake staff, and which were created by the software itself.
Audit logs can separate those steps. They may show when information entered the chart, whose credentials were used, what the physician changed, and whether additional actions occurred after the encounter ended.
A finalized order may therefore represent several decisions made by different people or systems. Reconstructing that sequence prevents the completed chart from being treated as proof that the physician personally approved every step.
Prescribing Data Can Make Legitimate Variation Look Like a Pattern
Telehealth allows physicians to treat patients across broad geographic areas and, where legally permitted, across state lines. A doctor may therefore generate prescribing volumes that look very different from those of a traditional local practice.
Investigators can sort that data by drug, dosage, geography, patient, and frequency. High volume or geographic concentration may become the basis for an allegation that prescriptions were issued without meaningful evaluation.
Specialty focus, recurring care, medication management, or the platform’s patient population may explain why one physician appears as an outlier. Aggregate statistics cannot show the medical reasoning behind each patient’s treatment.
Chart-level review may reveal substantial differences hidden by the data. Patients grouped under the same prescribing pattern may have different diagnoses, prior therapies, contraindications, or treatment histories that explain why the same medication was used.
Billing Can Occur Far From the Physician
A telehealth physician may complete the clinical encounter while another company handles coding, eligibility verification, claim submission, and payer appeals. The physician’s identifier may still appear on the claim.
Investigators may use that identifier to argue that the doctor understood how the service was billed. Platform agreements, access permissions, billing records, and compensation terms can show whether the physician ever reviewed the final claim or had authority to change it.
A national telehealth platform may create even more distance between care and reimbursement. The doctor may have no access to payer contracts, coding rules, reimbursement rates, or appeal decisions and may receive compensation unrelated to the amount billed for an individual encounter.
Claim-edit histories can show whether coding changed after the clinical work ended. Those edits may have been made by personnel the physician never met or communicated with, even though the final claim still carried the physician’s identifier.
New Technology Does Not Eliminate the Need to Prove Knowledge
Telemedicine gives prosecutors more electronic evidence, but the existence of more data does not mean every participant possessed the same information. Marketing staff may know how patients were acquired. Engineers may understand how the platform was designed. Billing personnel may know how claims were submitted. Physicians may see only the clinical information presented during the encounter.
Investigators can combine those records and describe the platform as one coordinated operation. Doing so may blur the line between information held somewhere within the company and information actually known by the individual physician.
Communications, access permissions, contract terms, and workflow records can show where those boundaries existed. They may also establish that a physician had no role in marketing strategy, coding, reimbursement, or automated decisions built into the platform.
Working with an experienced Florida healthcare fraud lawyer can help separate the physician’s clinical conduct from decisions made through technology, marketing, prescribing workflows, or billing systems outside the physician’s control.
Contact The Baez Law Firm
If you are facing a federal investigation involving telemedicine, investigators may already be using platform records to reconstruct how virtual care was delivered and billed. Those records need to be read in the context of the technology, the regulatory rules in effect at the time, and the physician’s actual role in the encounter.
At The Baez Law Firm, we represent physicians and healthcare professionals facing federal fraud allegations involving telehealth and other modern healthcare delivery models. Contact The Baez Law Firm today to speak with an experienced Florida healthcare fraud lawyer and learn how we can challenge allegations that virtual care was used as a vehicle for criminal healthcare fraud.
Source:
- 18 U.S.C. § 1347 – Health Care Fraud
uscode.house.gov/view.xhtml?edition=prelim&req=granuleid%3AUSC-prelim-title18-section1347 - 21 U.S.C. § 829 – Prescriptions
uscode.house.gov/view.xhtml?edition=prelim&f=treesort&jumpTo=true&num=0&req=%28title%3A21+section%3A829+edition%3Aprelim%29+OR+%28granuleid%3AUSC-prelim-title21-section829%29 - Drug Enforcement Administration – DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care
dea.gov/es/node/234606
